MX366003B - Metabolitos de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n' -(4-fluorofenil)ciclopropan-1,1-dicarboxamida. - Google Patents

Metabolitos de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n' -(4-fluorofenil)ciclopropan-1,1-dicarboxamida.

Info

Publication number
MX366003B
MX366003B MX2015012490A MX2015012490A MX366003B MX 366003 B MX366003 B MX 366003B MX 2015012490 A MX2015012490 A MX 2015012490A MX 2015012490 A MX2015012490 A MX 2015012490A MX 366003 B MX366003 B MX 366003B
Authority
MX
Mexico
Prior art keywords
metabolites
dicarboxamide
methyloxy
quinolin
cyclopropane
Prior art date
Application number
MX2015012490A
Other languages
English (en)
Other versions
MX2015012490A (es
Inventor
T Aftab Dana
Xu Wei
Naganathan Sriram
Lacy Steven
Nguyen Linh
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2015012490A publication Critical patent/MX2015012490A/es
Publication of MX366003B publication Critical patent/MX366003B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C305/00—Esters of sulfuric acids
    • C07C305/22—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings
    • C07C305/24—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pain & Pain Management (AREA)
  • Quinoline Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La invención se relaciona con metabolitos de cabozantinib (I), así como sus usos. Ver formula: I.
MX2015012490A 2013-03-15 2014-03-17 Metabolitos de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n' -(4-fluorofenil)ciclopropan-1,1-dicarboxamida. MX366003B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792413P 2013-03-15 2013-03-15
PCT/US2014/030524 WO2014145715A1 (en) 2013-03-15 2014-03-17 Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide

Publications (2)

Publication Number Publication Date
MX2015012490A MX2015012490A (es) 2016-05-24
MX366003B true MX366003B (es) 2019-06-24

Family

ID=50631091

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012490A MX366003B (es) 2013-03-15 2014-03-17 Metabolitos de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n' -(4-fluorofenil)ciclopropan-1,1-dicarboxamida.

Country Status (18)

Country Link
US (3) US10273211B2 (es)
EP (1) EP2970126B1 (es)
JP (1) JP6389238B2 (es)
KR (1) KR102276348B1 (es)
CN (1) CN105121412B (es)
AU (2) AU2014232714B2 (es)
BR (1) BR112015023109A2 (es)
CA (1) CA2907334C (es)
EA (1) EA033786B1 (es)
ES (1) ES2729626T3 (es)
GE (1) GEP20196995B (es)
HK (1) HK1220447A1 (es)
IL (1) IL241577B (es)
MX (1) MX366003B (es)
NZ (1) NZ712330A (es)
UA (1) UA119321C2 (es)
WO (1) WO2014145715A1 (es)
ZA (1) ZA201506842B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2621481B2 (en) 2010-09-27 2022-10-19 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
KR20190049907A (ko) 2011-02-10 2019-05-09 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
EP2844254A1 (en) 2012-05-02 2015-03-11 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CN105121412B (zh) 2013-03-15 2019-07-12 埃克塞里艾克西斯公司 N-(4-{[6，7-双(甲基氧基)喹啉-4-基]氧基}苯基)-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的代谢物
EP2981263B1 (en) 2013-04-04 2022-06-29 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
UA123534C2 (uk) 2014-02-14 2021-04-21 Екселіксис, Інк. Кристалічні тверді форми n-{4-[(6,7-диметоксихінолін-4-іл)окси]феніл}-n'-(4-флуорофеніл)циклопропан-1,1-дикарбоксаміду, способи отримання і способи застосування
MA39735A (fr) 2014-03-17 2017-01-25 Exelixis Inc Dosage de préparations de cabozantinib
US11124481B2 (en) 2014-07-31 2021-09-21 Exelixis, Inc. Method of preparing fluorine-18 labeled Cabozantinib and its analogs
CA2957466C (en) 2014-08-05 2023-10-17 Exelixis, Inc. Drug combinations to treat multiple myeloma
EP3442531A1 (en) 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN107556238A (zh) * 2016-06-30 2018-01-09 深圳万乐药业有限公司 一种卡博替尼的合成方法
CN117603138A (zh) 2018-01-26 2024-02-27 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
CN110423218A (zh) * 2019-08-09 2019-11-08 新乡双鹭药业有限公司 一种苹果酸卡博替尼合成中杂质的制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2925655T3 (es) 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
CA2572331A1 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
CA2603748A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
PL2101759T3 (pl) 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AR075084A1 (es) 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
MX2011005038A (es) 2008-11-13 2011-06-16 Exelisis Inc Metodo de preparacion de derivados de quinolina.
JP2012511017A (ja) 2008-12-04 2012-05-17 エグゼリクシス， インコーポレイテッド キノリン誘導体の調製方法
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
NZ597695A (en) 2009-07-17 2014-05-30 Exelixis Inc Crystalline forms of n-[3-fluoro-4-({ 6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl} oxy)phenyl]-n’-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
MX2012010506A (es) 2010-03-12 2012-10-15 Exelixis Inc Formas cristalinas hidratadas del n-[3-fluoro-4-({6-(metiloxi)-7-[ (3-morfolin-4-ilpropil)oxi]-quinolin-4-il}oxi)fenil]-n'-(4-fluoro fenil)ciclopropano-1,1-dicarboxamida.
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
CN103221035A (zh) 2010-07-16 2013-07-24 埃克塞里艾克西斯公司 C-met调节剂药物组合物
US20140186407A9 (en) 2010-07-16 2014-07-03 Exelixis Inc. C-Met Modulator Pharmaceutical Compositions
EP2621481B2 (en) 2010-09-27 2022-10-19 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
JP2013540759A (ja) 2010-09-27 2013-11-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
US20140057908A1 (en) 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
US20130252956A1 (en) 2010-11-22 2013-09-26 Howard Kallender Methods of treating cancer
CA2822283A1 (en) * 2010-12-23 2012-06-28 Nestec S.A. Drug selection for malignant cancer therapy using antibody-based arrays
CN102093421B (zh) 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
KR20190049907A (ko) 2011-02-10 2019-05-09 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
EA029506B1 (ru) 2011-05-02 2018-04-30 Экселиксис, Инк. Способ лечения рака и раковой боли в костях
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
EA201490676A1 (ru) 2011-09-22 2015-02-27 Экселиксис, Инк. Способ лечения остеопороза
TWI619694B (zh) 2011-10-20 2018-04-01 艾克塞里克斯公司 用於製備喹啉衍生物之方法
TW201818937A (zh) 2011-11-08 2018-06-01 美商艾克塞里克斯公司 治療癌症之方法
EP2844254A1 (en) 2012-05-02 2015-03-11 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
US20150238477A1 (en) 2012-09-07 2015-08-27 Exelixis, Inc. Method of Treating Lung Adenocarcinoma
CN103664776B (zh) * 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
US20140221372A1 (en) 2013-02-06 2014-08-07 GlaxoSmithKline Intellectual Property (NO 2.) Limited Method of administration and treatment
CN105121412B (zh) 2013-03-15 2019-07-12 埃克塞里艾克西斯公司 N-(4-{[6，7-双(甲基氧基)喹啉-4-基]氧基}苯基)-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的代谢物
WO2014145693A1 (en) * 2013-03-15 2014-09-18 Exelixis, Inc. Metabolites of n-[3-fluoro-4-({ 6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
EP2981263B1 (en) 2013-04-04 2022-06-29 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
JP2016515628A (ja) 2013-04-04 2016-05-30 エグゼリクシス， インコーポレイテッド 癌を治療するための複合薬
UA123534C2 (uk) 2014-02-14 2021-04-21 Екселіксис, Інк. Кристалічні тверді форми n-{4-[(6,7-диметоксихінолін-4-іл)окси]феніл}-n'-(4-флуорофеніл)циклопропан-1,1-дикарбоксаміду, способи отримання і способи застосування
MA39735A (fr) * 2014-03-17 2017-01-25 Exelixis Inc Dosage de préparations de cabozantinib
US11124481B2 (en) * 2014-07-31 2021-09-21 Exelixis, Inc. Method of preparing fluorine-18 labeled Cabozantinib and its analogs

Also Published As

Publication number Publication date
CN105121412B (zh) 2019-07-12
AU2014232714A1 (en) 2015-10-08
AU2014232714B2 (en) 2018-07-19
IL241577B (en) 2019-11-28
UA119321C2 (uk) 2019-06-10
ZA201506842B (en) 2017-08-30
KR102276348B1 (ko) 2021-07-12
AU2018204666A1 (en) 2018-07-19
CN105121412A (zh) 2015-12-02
EP2970126B1 (en) 2019-03-06
JP2016516074A (ja) 2016-06-02
EP2970126A1 (en) 2016-01-20
US10273211B2 (en) 2019-04-30
NZ712330A (en) 2020-04-24
HK1220447A1 (zh) 2017-05-05
US20160031818A1 (en) 2016-02-04
ES2729626T3 (es) 2019-11-05
US20210002228A1 (en) 2021-01-07
KR20150130376A (ko) 2015-11-23
CA2907334C (en) 2021-12-07
WO2014145715A1 (en) 2014-09-18
US20190218182A1 (en) 2019-07-18
CA2907334A1 (en) 2014-09-18
GEP20196995B (en) 2019-07-25
BR112015023109A2 (pt) 2018-05-15
EA033786B1 (ru) 2019-11-26
EA201591756A1 (ru) 2016-02-29
MX2015012490A (es) 2016-05-24
JP6389238B2 (ja) 2018-09-12

Similar Documents

Publication Publication Date Title
MX366003B (es) Metabolitos de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n' -(4-fluorofenil)ciclopropan-1,1-dicarboxamida.
EA201490676A1 (ru) Способ лечения остеопороза
EA201691850A1 (ru) Дозирование составов, содержащих кабозантиниб
PH12016500467A1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
RS52754B (en) MALATE IS N- (4- {[6,7-BIS (METHYLOXY) HINOLIN-4-IL] OXY} PHENYL-N'- (4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMID, AND ITS CRYSTAL FORMS FOR CARCINOMA TREATMENT
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
GEP20207177B (en) Pyridone amides as modulators of sodium channels
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
EA201591451A1 (ru) Модуляторы flap
MX2016001138A (es) Compuestos de benzoxaborol triciclico, metodo de preparacion y uso del mismo.
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
EA201491517A1 (ru) N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения
IN2013MU03862A (es)
MX2020006436A (es) Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
MX2016005539A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
IN2014KN02584A (es)
UA89726U (ru) Применение n,n'-(этан-1,2-диил)бис(хинолин-2-карбоксамида) как средства с гипогликемическим действием
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.
UA116811C2 (uk) Комплекси агомелатину та сульфонових кислот, спосіб їх одержання та фармацевтичні композиції, що їх містять
EA201700037A1 (ru) Производные 2н-хромена в качестве анальгезирующих средств

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted